Fenwick Represents Synthego in Sale to Perceptive Advisors

Fenwick is representing Synthego, a provider of CRISPR solutions, in its pending sale to Perceptive Advisors, a global life sciences investor known for backing leading biotech companies.

The transaction will provide Synthego with a strengthened balance sheet and a clear path to expand its product portfolio, make strategic investments and empower clients to advance curative therapeutics worldwide. More information can be obtained from Synthego’s announcement.

The Fenwick transaction team includes corporate partners Ethan Skerry and Steven Levine.